Volunteer Blood Donors with Antibody to Hepatitis C Virus: Clinical, Biochemical, Virologic, and Histologic Features

Shakil, A. Obaid; Conry‐Cantilena, Cathy; Alter, Harvey J.; Hayashi, Paul H.; Kleiner, David E.; Tedeschi, Valeria; Krawczynski, Krzysztof; Conjeevaram, Hari S.; Sallie, Richard; Bisceglie, Adrian M. Di

doi:10.7326/0003-4819-123-5-199509010-00002

Cited by 250 publications

(142 citation statements)

References 0 publications

Supporting

Mentioning

125

Contrasting

Unclassified

Order By: Relevance

“…Of those with HCV infection, 13.2% had undetectable HCV RNA; very similar to that observed in other studies (15-45%) [26,27]. Of note is that the population studied did not have any biochemical evidence of an elevated grade of fibrosis, as had been described previously [28,29].…”

Section: Discussionsupporting

confidence: 73%

Hepatitis C and B prevalence in Spanish prisons

Hoya¹,

Marco²,

García-Guerrero³

et al. 2011

Eur J Clin Microbiol Infect Dis

View full text Add to dashboard Cite

Purpose: The Prevalhep study seeks to determine the prevalence of factors associated with hepatitis C virus (HCV) and B (HBV) in Spanish prisoners Methods: Observational, cross-sectional study which randomly selected 18 Spanish prisons to participate, and with 21 prisoners/CentreResults: There were 378 prisoners selected, 370 of whom had serological HCV and 342 had VHB data. The HCV population were predominantly male (91.6%), of middle age (66.7% contact status with HBV (HBcAb+ and/or HBsAg+), while 37.5% were susceptible to HB. Conclusions:The prevalence of HBV and HCV has decreased in the Spanish prison population, probably as a result of decrease in IDU transmission, and an increase in immigrant prisoner population that does not have this risk behaviour.[Word count = 198]

show abstract

Section: Discussionsupporting

confidence: 73%

Hepatitis C and B prevalence in Spanish prisons

Hoya¹,

Marco²,

García-Guerrero³

et al. 2011

Eur J Clin Microbiol Infect Dis

View full text Add to dashboard Cite

show abstract

“…A subset of patients from the cohort had two liver biopsies performed separated by 6 months or more and without receiving therapy between the two biopsies. This group consisted of 59 blood donors enrolled in a study of the natural history of hepatitis C, 22 52 untreated control patients who were participating in randomized trials evaluating interferon alfa or ribavirin, 23,24 and 30 patients who were referred for evaluation and possible therapy who elected not to undergo treatment. 4 A proportion of these patients were the subject of a previous report on fibrosis; however, steatosis was not specifically analyzed.…”

Section: Methodsmentioning

confidence: 99%

Steatosis and progression of fibrosis in untreated patients with chronic hepatitis C infection

et al. 2006

View full text Add to dashboard Cite

Hepatic steatosis is common in patients with chronic hepatitis C (CHC) and is reported to be a risk factor for progression of fibrosis. The aims of this study were to evaluate the interactions between hepatic steatosis and fibrosis in a well-defined cohort of patients with CHC. The computerized pathology database at the National Institutes of Health Clinical Center was searched for patients with CHC who had undergone liver biopsy between 1980 and 2003. Biopsies were scored for necroinflammation using a modified histology activity index, fibrosis using the Ishak system, and steatosis as either none (<5% of cells), mild (5%-25%), or moderate-to-severe (>25%). Four hundred ninety-four patients were identified. The mean age was 44 ؎ 9.8 years; 60% were male, 80% Caucasian, and 65% were infected with genotype 1. Steatosis was mild in 31% and moderate to severe in 9% of patients. In univariate analysis, steatosis was associated with increased age, body weight, body mass index (BMI), alanine aminotransferase (ALT) levels, histological necroinflammatory activity, and fibrosis. However, in multivariate analysis, steatosis was associated only with increased age, BMI, and ALT levels and not with fibrosis. One hundred thirty-six patients had 2 liver biopsies separated by 0.5 to 17 years. Worsening of fibrosis occurred in 40% of patients and correlated independently with increasing age, periportal necroinflammation, and ALT elevations but not with steatosis. In conclusion, in this cohort of patients with CHC, steatosis was associated with older age, higher BMI, and higher serum ALT levels but not with the presence of or subsequent progression of fibrosis. (HEPATOLOGY 2006;43: 780-787.)

show abstract

“…Twenty five patients (51%) had chronic hepatitis, most of them grading from A1 to A2. Seventeen out of 25 patients (68%) had fibrosis, while other studies reported results ranging from 41% to 90% (22,26) . Interestingly, one of our patients showed cirrhosis.…”

Section: Discussionmentioning

confidence: 60%

“…The frequency of anti-HCV in blood donors varies from about 1% to 2%, according to the geographic area and the population studied (24) . HCV is the pathogen related with 80% to 90% post-transfusional hepatitis (10,26) . In the present study, the main laboratorial alterations occurred in ALT and AST levels that were above normal in 85.7% and 73.5% of the blood donors, respectively (Table 2).…”

Section: Discussionmentioning

confidence: 99%

Relationship between serum concetrations of type III procollagen, hyluronic acid and histopathological findings in the liver of HCV-positive blood donors

Camacho

Silveira

Oliveira

et al. 2007

Arq. Gastroenterol.

View full text Add to dashboard Cite

-Background -Serologic markers have been proposed for monitoring hepatic fibrosis in chronic liver disease. Among fibrosis markers, type III procollagen (PIIIP) and hyaluronic acid have been studied in these patients. Aim -To evaluate the association between these serum markers with histological findings. Methods -A prospective cross-sectional study was carried out with HCV-positive blood donors. The studied population included men and women whose age ranged from 18 to 60 years, with elevated liver function tests [ALT levels ≥ 1.5 times the normal value and alterations of two or more of the following: any changes in the levels of ALT, aspartate aminotransferase, conjugated bilirrubin, gammaglobulin, gammaglutamyltranspeptidase, albumin, platelet count; alkaline phosphatase levels ≥1.5 times the normal value, or prothrombin time below 70% and above 60%]. Fourty-nine patients were submitted to liver biopsy, blood analysis of PIIIP, hyaluronic acid, besides liver function tests.

show abstract

Volunteer Blood Donors with Antibody to Hepatitis C Virus: Clinical, Biochemical, Virologic, and Histologic Features

Cited by 250 publications

References 0 publications

Hepatitis C and B prevalence in Spanish prisons

Hepatitis C and B prevalence in Spanish prisons

Steatosis and progression of fibrosis in untreated patients with chronic hepatitis C infection

Relationship between serum concetrations of type III procollagen, hyluronic acid and histopathological findings in the liver of HCV-positive blood donors

Contact Info

Product

Resources

About